Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.36 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929244 | 0.92 | PKM (0.46) | PKMTSHRSIGMAR1MEN1KMT2A | |
| SCHEMBL13951540 | 0.88 | OGA (0.43) | PKMTSHRSIGMAR1MEN1KMT2A | |
| SCHEMBL13929262 | 0.85 | SIGMAR1 (0.48) | PKMTSHRSIGMAR1MEN1KMT2A | |
| SCHEMBL13929260 | 0.82 | PKM (0.46) | PKMTSHRSIGMAR1F2F10 | |
| SCHEMBL13929259 | 0.81 | RORC (0.44) | SIGMAR1MEN1KMT2AF2F10 | |
| SCHEMBL13929264 | 0.81 | SIGMAR1 (0.47) | PKMTSHRSIGMAR1F2F10 | |
| SCHEMBL13929263 | 0.80 | PKM (0.54) | PKMTSHRSIGMAR1CCR3OPRM1 | |
| SCHEMBL13929239 | 0.78 | PKM (0.52) | PKMTSHRSIGMAR1CCR3 | |
| SCHEMBL13929291 | 0.77 | SIGMAR1 (0.46) | PKMTSHRSIGMAR1CCR3OPRM1 | |
| SCHEMBL13929242 | 0.77 | SIGMAR1 (0.51) | PKMTSHRSIGMAR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | PKM 3209/4885TSHR 636/4885SIGMAR1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.